Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake.
BACKGROUND
Peptide YY (PYY(3-36)) infused to levels within the physiological range reduces appetite and food intake in humans without nausea. However, PYY(3-36) has previously been shown to cause nausea at higher doses.


METHODS
We studied the relationship of PYY(3-36), nausea and food intake in six volunteers, using three different PYY(3-36) preparations infused to achieve supraphysiological PYY plasma levels.


RESULTS
Supraphysiological levels of PYY caused nausea in five subjects (P < 0.05). Although PYY(3-36) increased satiety (P < 0.05) and reduced food intake (P < 0.05), no greater enhancement of satiety or inhibition of food intake was observed compared with previous reports.


CONCLUSIONS
This study cautions against the use of supraphysiological doses of PYY(3-36) as it may increase nausea with no benefit in food reduction.
le Roux
Carel W
CW
Department of Metabolic Medicine, 6th Floor Commonwealth Building, Hammersmith Hospital, Imperial College London, London, UK.
Borg
Cynthia M
CM
Murphy
Kevin G
KG
Vincent
Royce P
RP
Ghatei
Mohammad A
MA
Bloom
Stephen R
SR
D004435:Eating / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009325:Nausea / Q000139:chemically induced*; D010446:Peptide Fragments; D019894:Peptide YY / Q000008:administration & dosage* / Q000819:agonists*
D010446:Peptide Fragments; D019894:Peptide YY; C061785:peptide YY (3-36)